Moreover, in glioblastoma, HOTTIP shows conflicting roles, being downregulated in some studies, which leads to reduced tumor growth through the suppression of cell cycle regulators like CDK2 and cyclin A. Finally, in esophageal cancer, HOTTIP mediates chemotherapeutic resistance by activating ABCG2, affecting treatment outcomes. Here, CDK2 is linked to glioblastoma.